AGIO (Agios Pharmaceuticals) Institutional Ownership: 115.47% (As of Jul. 12, 2026)


AGIO Agios Pharmaceuticals Inc AGIO
44 GF Score
Price $41.23
GF Value $84.69
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Institutional Ownership?

Agios Pharmaceuticals AGIO -3.65% 44 Institutional Ownership is 115.47% as of Jul. 12, 2026. GuruFocus rates AGIO with a GF Score™ of 44/100 and a GF Value™ of $84.69 (Possible Value Trap). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Agios Pharmaceuticals's institutional ownership is 115.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Agios Pharmaceuticals's Insider Ownership is 2.67%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Agios Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 98.97%.

Agios Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Institutional Ownership Chart

Agios Pharmaceuticals Historical Data

The historical data trend for Agios Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 54.56 54.28 52.71 53.01 52.81 54.41 55.35 54.67 54.65 55.04
AGIO
44GF Score
Agios Pharmaceuticals Inc AGIO
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 115.47% mean?
Agios Pharmaceuticals (AGIO) has a Institutional Ownership of 115.47% as of Jul. 12, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Institutional Ownership too high?
Agios Pharmaceuticals' current Institutional Ownership is 115.47%. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Institutional Ownership compare to ABCL and KOD?
Agios Pharmaceuticals' Institutional Ownership of 115.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Institutional Ownership is 115.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (AGIO) is currently considered Possible Value Trap. The stock's GF Value™ is $84.69, compared to a current price of $41.23 — trading 51.3% below its estimated fair value. The current Institutional Ownership is 115.47%. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Agios Pharmaceuticals (AGIO), the current Institutional Ownership is 115.47% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (AGIO) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of $41.23 is trading 51.3% below its estimated GF Value™ of $84.69. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for AGIO:

  • Institutional Ownership: 115.47%
  • GF Value™: $84.69 vs. price of $41.23 (51.3% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges 0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score

Get the complete analysis for AGIO

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.23
Price
$84.69
GF Value